statistiche ricercatore

Continente	#
EU - Europa	2.244
NA - Nord America	869
AS - Asia	550
SA - Sud America	92
Continente sconosciuto - Info sul continente non disponibili	30
AF - Africa	23
Totale	3.808

Nazione	#
FI - Finlandia	1.893
US - Stati Uniti d'America	838
SG - Singapore	201
IT - Italia	140
CN - Cina	112
BR - Brasile	71
VN - Vietnam	63
PL - Polonia	47
DE - Germania	43
HK - Hong Kong	41
TW - Taiwan	40
GB - Regno Unito	27
BD - Bangladesh	23
CA - Canada	19
FR - Francia	17
JP - Giappone	15
RU - Federazione Russa	14
ID - Indonesia	13
TR - Turchia	11
IN - India	10
SE - Svezia	9
UA - Ucraina	9
AT - Austria	6
BE - Belgio	6
CO - Colombia	6
ES - Italia	6
MX - Messico	6
NL - Olanda	6
AR - Argentina	5
DK - Danimarca	5
EG - Egitto	5
ZA - Sudafrica	5
ET - Etiopia	4
IQ - Iraq	4
VE - Venezuela	4
AL - Albania	3
EC - Ecuador	3
JO - Giordania	3
KE - Kenya	3
CR - Costa Rica	2
LT - Lituania	2
MY - Malesia	2
PK - Pakistan	2
PY - Paraguay	2
RO - Romania	2
TN - Tunisia	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BB - Barbados	1
CH - Svizzera	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EE - Estonia	1
GR - Grecia	1
GT - Guatemala	1
HU - Ungheria	1
IS - Islanda	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LV - Lettonia	1
MA - Marocco	1
MU - Mauritius	1
PE - Perù	1
PH - Filippine	1
PR - Porto Rico	1
SD - Sudan	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TT - Trinidad e Tobago	1
Totale	3.778

Nome	#
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study	2.112
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial	383
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy	310
Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes	216
ErbB2‐NOTCH1 axis controls autophagy in cardiac cells	179
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study	176
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer	167
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer	138
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)	127
Totale	3.808

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	42	0	0	5	3	1	1	7	3	2	5	3	12
2022/2023	76	8	8	3	7	8	10	5	11	10	1	5	0
2023/2024	76	1	12	4	1	7	11	2	2	1	6	16	13
2024/2025	308	6	12	23	11	30	30	10	14	57	28	45	42
2025/2026	2.830	87	41	64	85	128	70	114	79	1.946	100	73	43
2026/2027	155	46	50	59	0	0	0	0	0	0	0	0	0
Totale													3.808

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara